NC
ANIK icon

Northpointe Capital’s Anika Therapeutics ANIK Stock Holding History

Northpointe Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-152,350
Closed -$5.81M – 236
2013
Q4 		$5.81M Hold
152,350
– – 0.51% 68
2013
Q3 		$3.65M Buy
152,350
+104,015
+215% +$2.33M 0.43% 71
2013
Q2 		$822K Buy
+48,335
New +$697K 0.09% 151

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $5.02B AUM 66.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northpointe Capital's ANIK Position: Q1 2014 in Review

Northpointe Capital sold out of Anika Therapeutics (ANIK) in Q1 2014, closing a stake of 152,350 shares — an estimated $5.81M sold.

Northpointe Capital first reported a position in ANIK in Q2 2013 and held it in 3 quarters. The position peaked at $5.81M in Q4 2013. 153 funds tracked by Wall St. Rank hold ANIK as of Q1 2014.

  • Northpointe Capital reported no remaining Anika Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Northpointe Capital sold 152,350 Anika Therapeutics shares in Q1 2014, an estimated $5.81M.
  • Northpointe Capital first reported a position in Anika Therapeutics in Q2 2013 and held it in 3 quarters.
  • Northpointe Capital's Anika Therapeutics position peaked at $5.81M in Q4 2013.
  • 153 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2014.

Based on Northpointe Capital's 13F filing for Q1 2014, filed 6 May 2014.